Indaptus Therapeutics (INDP) vs Lyell Immunopharma (LYEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Indaptus Therapeutics (INDP) has outperformed Lyell Immunopharma (LYEL) over the past year, gaining 52.4% versus a loss of 27.9%. Over five years, LYEL leads with a -92.6% price change compared with -98.3% for INDP. Lyell Immunopharma is the larger company by market cap ($441.8 million vs $433.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INDP | LYEL |
|---|---|---|
| Share price | $2.82 | $13.80 |
| Market cap | $433.16M | $441.82M |
| 1-day change | -9.90% | +1.62% |
| YTD return | -3.09% | -55.17% |
| 1-year return | +52.43% | -27.86% |
| 5-year return | -98.26% | -92.59% |
| EPS (TTM) | $-3.16 | $-12.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $36.00K |
| Revenue growth (YoY) | — | -40.98% |
| Net income (latest FY) | $-20.85M | $-274.45M |
| Operating margin | — | -748344.44% |
| Net margin | — | -762355.56% |
| 52-week high | $5.96 | $45.00 |
| 52-week low | $0.92 | $7.20 |
| Distance from 52-week high | -52.68% | -69.33% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +172.68% |
| Average volume | 712.87K | 174.76K |
| Shares outstanding | 153.60M | 32.02M |
| Employees | 5 | 161 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INDP has outperformed LYEL by 80.3 percentage points over the past year.
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
About Lyell Immunopharma
LYEL stock →Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees
INDP vs LYEL FAQ
Which is bigger, Indaptus Therapeutics or Lyell Immunopharma?
Lyell Immunopharma (LYEL) is larger, with a market capitalization of $441.82M compared with $433.16M for Indaptus Therapeutics (INDP).
Which stock has performed better over the past year, INDP or LYEL?
INDP returned +52.43% over the past 12 months, compared with -27.86% for LYEL (price return, excluding dividends). Past performance does not predict future results.
Are Indaptus Therapeutics and Lyell Immunopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.